Bertolt Kreft

Pharmaceutical R&D
Berlin, BE 13342, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity.

Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity.

Journal: Journal for immunotherapy of cancer

Published: June 24, 2026

Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer.

Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer.

Journal: Journal of medicinal chemistry

Published: September 27, 2024

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: October 08, 2023

T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction.

T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction.

Journal: Oncoimmunology

Published: February 10, 2022

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

Journal: Journal of medicinal chemistry

Published: April 28, 2020

Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2).

Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2).

Journal: Cancer immunology research

Published: May 08, 2019

Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.

Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.

Journal: Molecular cancer therapeutics

Published: July 20, 2016

Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.

Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.

Journal: Cancer research

Published: January 18, 2016

Functional and Structural Characterization of Bub3·BubR1 Interactions Required for Spindle Assembly Checkpoint Signaling in Human Cells.

Functional and Structural Characterization of Bub3·BubR1 Interactions Required for Spindle Assembly Checkpoint Signaling in Human Cells.

Journal: The Journal of biological chemistry

Published: November 02, 2015

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.

Journal: Molecular cancer therapeutics

Published: June 17, 2015

Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.

Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.

Journal: Cancer medicine

Published: April 14, 2014

Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.

Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.

Journal: Molecular cancer therapeutics

Published: April 10, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026